Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
Status:
Completed
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in
new users of the 52mg levonorgestrel-releasing intrauterine device (IUD). Half of
participants will receive a course of tamoxifen three weeks after insertion of the IUD, while
the other half of participants will receive a course of placebo.